Previous close | 27.40 |
Open | 22.90 |
Bid | 21.00 |
Ask | 27.40 |
Strike | 340.00 |
Expiry date | 2024-01-19 |
Day's range | 22.90 - 26.00 |
Contract range | N/A |
Volume | |
Open interest | 68 |
Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market. Vertex and AbbVie also happen to offer a lot of growth potential. Vertex has a new potential blockbuster drug on the horizon.
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $308.47, marking a -1.88% move from the previous day.
BOSTON & ZUG, Switzerland, March 27, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D).